Levin, Adeera

KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease

Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International

Chronic Kidney Disease and DiabetesDialysis and Renal Disease Management

Cited by 8,530

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 6,189

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

Levey, A. S., Coresh, J., Balk, E., Kausz, A. T., Levin, A., Steffes, M. W., Hogg, R. J., Perrone, R. D., Lau, J., & Eknoyan, G. (2003) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 4,615

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet

Lipoproteins and Cardiovascular HealthChronic Kidney Disease and Diabetes

Cited by 2,479

Evolving importance of kidney disease: from subspecialty to global health burden

Eckardt, K.-U., Coresh, J., Devuyst, O., Johnson, R. J., Köttgen, A., Levey, A. S., & Levin, A. (2013) · The Lancet

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 1,159

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis

Neuen, B. L., Young, T., Heerspink, H. J. L., Neal, B., Perkovic, V., Billot, L., Mahaffey, K. W., Charytan, D. M., Wheeler, D. C., Arnott, C., et al. (2019) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 893

Prevalent left ventricular hypertrophy in the predialysis population: identifying opportunities for intervention

Levin, A., Singer, J., Thompson, C. R., Ross, H., & Lewis, M. (1996) · American Journal of Kidney Diseases

Cardiovascular Function and Risk FactorsChronic Kidney Disease and Diabetes

Cited by 709

Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency

Levey, A. S., Gansevoort, R. T., Coresh, J., Inker, L. A., Heerspink, H. L., Grams, M. E., Greene, T., Tighiouart, H., Matsushita, K., Ballew, S. H., et al. (2020) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 591

Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies

Coresh, J., Heerspink, H. J. L., Sang, Y., Matsushita, K., Arnlov, J., Astor, B. C., Black, C., Brunskill, N. J., Carrero, J.-J., Feldman, H. I., et al. (2019) · The Lancet Diabetes & Endocrinology

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 338

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial

Mahaffey, K. W., Jardine, M. J., Bompoint, S., Cannon, C. P., Neal, B., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., et al. (2019) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 291

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics

Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 234

Corticosteroid therapy in IgA nephropathy

Lv, J., Xu, D., Perkovic, V., Ma, X., Johnson, D. W., Woodward, M., Levin, A., Zhang, H., & Wang, H. (2012) · Journal of the American Society of Nephrology

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 190

Early change in albuminuria with canagliflozin predicts kidney and cardiovascular outcomes: a post hoc analysis from the CREDENCE Trial

Oshima, M., Neuen, B. L., Li, J., Perkovic, V., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., Mahaffey, K. W., et al. (2020) · Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 176

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Oshima, M., Jardine, M. J., Agarwal, R., Bakris, G., Cannon, C. P., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Levin, A., et al. (2021) · Kidney International

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 166

Atrasentan in Patients with IgA Nephropathy

Heerspink, H. J. L., Jardine, M., Kohan, D. E., Lafayette, R. A., Levin, A., Liew, A., Zhang, H., Lodha, A., Gray, T., Wang, Y., et al. (2025) · New England Journal of Medicine

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 142

Effects of Canagliflozin in Patients with Baseline eGFR <30 ml/min per 1.73 m2: Subgroup Analysis of the Randomized CREDENCE Trial

Bakris, G., Oshima, M., Mahaffey, K. W., Agarwal, R., Cannon, C. P., Capuano, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., et al. (2020) · Clinical Journal of the American Society of Nephrology

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 142

Effects of canagliflozin on anaemia in patients with type 2 diabetes and chronic kidney disease: a post-hoc analysis from the CREDENCE trial

Oshima, M., Neuen, B. L., Jardine, M. J., Bakris, G., Edwards, R., Levin, A., Mahaffey, K. W., Neal, B., Pollock, C., Rosenthal, N., et al. (2020) · The Lancet Diabetes & Endocrinology

Erythropoietin and Anemia TreatmentDiabetes Treatment and Management

Cited by 135

International consensus definitions of clinical trial outcomes for kidney failure: 2020

Levin, A., Agarwal, R., Herrington, W. G., Heerspink, H. L., Mann, J. F. E., Shahinfar, S., Tuttle, K. R., Donner, J.-A., Jha, V., Nangaku, M., et al. (2020) · Kidney International

Chronic Kidney Disease and DiabetesStatistical Methods in Clinical Trials

Cited by 125

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease According to Baseline HbA1c, Including Those With HbA1c <7%: Results From the CREDENCE Trial

Cannon, C. P., Perkovic, V., Agarwal, R., Baldassarre, J., Bakris, G., Charytan, D. M., de Zeeuw, D., Edwards, R., Greene, T., Heerspink, H. J. L., et al. (2020) · Circulation

Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes

Cited by 117

Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial

Ye, N., Jardine, M. J., Oshima, M., Hockham, C., Heerspink, H. J. L., Agarwal, R., Bakris, G., Schutte, A. E., Arnott, C., Chang, T. I., et al. (2021) · Circulation

Blood Pressure and Hypertension StudiesDiabetes Treatment and Management

Cited by 115

Remembering the forgotten non-communicable diseases

Lopez, A. D., Williams, T. N., Levin, A., Tonelli, M., Singh, J. A., Burney, P. G., Rehm, J., Volkow, N. D., Koob, G., & Ferri, C. P. (2014) · BMC Medicine

Global Health and EpidemiologyHealthcare Systems and Public Health

Cited by 108

Canagliflozin and kidney-related adverse events in type 2 diabetes and CKD: findings from the randomized CREDENCE trial

Heerspink, H. J. L., Oshima, M., Zhang, H., Li, J., Agarwal, R., Capuano, G., Charytan, D. M., Craig, J., de Zeeuw, D., Di Tanna, G. L., et al. (2022) · American Journal of Kidney Diseases

Chronic Kidney Disease and DiabetesDiabetes Treatment and Management

Cited by 56

Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trial

Heerspink, H. J. L., Jardine, M. J., Kohan, D. E., Lafayette, R., Levin, A., Liew, A., Zhang, H., Noronha, I. L., Mastroianni-Kirsztajn, G., Chow, S., et al. (2026) · The Lancet

Renal Diseases and GlomerulopathiesChronic Kidney Disease and Diabetes

Cited by 12